What is the efficacy of erythropoiesis-stimulating agents (ESAs) for the treatment of anemia of chronic disease and renal failure?

Updated: Nov 27, 2018
  • Author: Edgar V Lerma, MD, FACP, FASN, FAHA, FASH, FNLA, FNKF; Chief Editor: Emmanuel C Besa, MD  more...
  • Print
Answer

Answer

A systematic review and meta-analysis published in 2016 found that ESA treatment of anemia to obtain higher hemoglobin targets did not result in important differences in health-related quality of life in patients with CKD. [21]

The NEPHRODIAB2 Prospective Randomized Controlled Open-Labelled Trial Comparing Effect of Two Haemoglobin levels, which was conducted in patients with type 2 diabetes mellitus and stage 3-4 CKD, found that raising hemoglobin to the normal range (130-140 g/L) with ESA treatment was safe but did not significantly slow renal function decline and increased treatment cost.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!